Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ heise+ | Hybrid-SUV Opel Grandland im Test: Für Wenigfahrer (Heise) +++ STELLANTIS Aktie +3,13%

TAKEDA ADR Aktie

 >TAKEDA ADR Aktienkurs 
12.9 EUR    +0.8%    (Tradegate)
Ask: 13.1 EUR / 781 Stück
Bid: 12.9 EUR / 797 Stück
Tagesumsatz: 700 Stück
Realtime Kurs von 8 bis 22 Uhr!
TAKEDA ADR Aktie über LYNX handeln
>TAKEDA ADR Performance
1 Woche: -4,5%
1 Monat: 0%
3 Monate: -9,6%
6 Monate: +0,4%
1 Jahr: +7,6%
laufendes Jahr: 0%
>TAKEDA ADR Aktie
Name:  TAKEDA PHARMACEUTICAL ADR
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US8740602052 / A1CWZF
Symbol/ Ticker:  TKDA (Frankfurt) / TAK (NYSE)
Kürzel:  FRA:TKDA, ETR:TKDA, TKDA:GR, NYSE:TAK
Index:  -
Webseite:  https://www.takeda.com/
Marktkapitalisierung:  40890 Mio. EUR
Umsatz:  3962469.02 Mio. EUR
EBITDA:  1046853.17 Mio. EUR
Gewinn je Aktie:  0.173 EUR
Schulden:  4386401.29 Mio. EUR
Liquide Mittel:  333184.81 Mio. EUR
Umsatz-/ Gewinnwachstum:  0.2% / -
KGV/ KGV lG:  64.25 / 14.27
KUV/ KBV/ PEG:  1.51 / 0.97 / 0.42
Gewinnm./ Eigenkapitalr.:  2.36% / 1.52%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / 4.77%
Div. Historie:  06.09.18 - 0.0158€
08.03.18 - 0.0801€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  TAKEDA ADR, TAKEDA
Letzte Datenerhebung:  24.06.25
>TAKEDA ADR Eigentümer
Aktien: 3120 Mio. St.
f.h. Aktien: 1580 Mio. St.
Insider Eigner: 0.01%
Instit. Eigner: 2.3%
 >TAKEDA ADR Anleihen 
Es sind 6 Anleihen zur TAKEDA ADR Aktie bekannt.
>TAKEDA ADR Peer Group

 
18.06.25 - 23:54
Wisner Baum: Ninth Circuit Affirms Actos RICO Class Action Certification Against Takeda and Eli Lilly (PR Newswire)
 
Appellate Court upholds decision in first-ever non-settlement national RICO class action lawsuit certified against a major pharmaceutical company, with potential damages exceeding $7 billion. SAN FRANCISCO, June 18, 2025 /PRNewswire/ -- The U.S. Court of Appeals for the Ninth Circuit......
09.06.25 - 19:06
Takeda′s downsized bond offering reveals new investor caution (Nikkei)
 
Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...
07.06.25 - 16:42
Takeda CEO Christophe Weber faces opposition to board reelection (Nikkei)
 
Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...
05.06.25 - 11:33
Corporate News: Best Places to Work (EQS)
 
Takeda Ukraine & Bulgaria Earn #8 Global Ranking in Best Places to Work 2024...
04.06.25 - 17:03
Biocom California Appoints New Members to Its Board of Directors and Board of Governors (Business Wire)
 
SOUTH SAN FRANCISCO, Calif. & LOS ANGELES & SAN DIEGO--(BUSINESS WIRE)--Biocom California, the association representing the California life science industry, today announced the appointment of Thierry Diagana, Ph.D., head of Global Health and California sites head for Novartis Biomedical Research; Stephen Hatke, vice president of operations and site head at Takeda's Thousand Oaks facility; and Kelly Hayes, assurance partner at Ernst & Young, to its board of directors. Additionally, Adam Lenain, member at Mintz Levin; Aaron K. Cohen, vice president, government affairs and public policy at Neurocrine Biosciences; and Diane Simeone, M.D., director of the Moores Cancer Center at University of California San Diego, were appointed to the board of governors. “The addition of these accomplished leaders, scientists and policy changers brings strategic depth to our board of directors and board of governors,” said Tim Scott, president and CEO of Biocom California. “Their expertise in capital raising, public p...
03.06.25 - 18:12
Takeda, Pfizer′s Adcetrix wins EU approval for hodgkin lymphoma treatment (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
03.06.25 - 17:18
Takeda′s ADCETRIS Combo Approved In EU For Advanced Hodgkin Lymphoma (AFX)
 
TOKYO (dpa-AFX) - Takeda (TAK), Tuesday announced that the European Commission has approved ADCETRIS combined with etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone for newl......
26.05.25 - 05:01
Chisato Iwai Clinches Her 1st LPGA Victory (Nippon)
 
Playa del Carmen, Mexico, May 25 (Jiji Press)--Chisato Iwai won the Mexico Riviera Maya Open by six shots on Sunday, clinching her first LPGA title. The 22-year-old finished at 12-under 276 at El Camaleon, becoming the third Japanese woman to claim an LPGA title this season after Rio Takeda and Mao Saigo. "I'm very delighted" Iwai said. "Despite a wide lead, my feelings didn't change.......
22.05.25 - 14:03
Alloy Therapeutics Enters Japanese Market by Establishing Operations at Shonan Health Innovation Park (Business Wire)
 
US-based biotech ecosystems company establishes subsidiary in key Japanese market with launch of its first cell therapy base in Japan, a key modality for Alloy to fully advance its proprietary iCAR-T technology. TOKYO & BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, has recently opened its first location in Japan – at Shonan iPark in Kanagawa, one of the world's most advanced research facilities, where it is establishing a cell therapy base. To support its expansion into Japan, Alloy has formed Alloy Therapeutics Co., Ltd. and appointed Yoshihide Ishii (Victor Stone) as Chief Executive Officer of its Japanese subsidiary. Building on collaboration with Takeda announced in November 2024, Alloy will advance cell therapy leveraging its proprietary iCAR-T technology. Originating with the groundbreaking iPSC research of Nobel Laureate Shinya Yamanaka, the iCAR-T platform was devel...
19.05.25 - 19:00
Veeva down after Takeda chooses Salesforce Life Sciences Cloud (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.05.25 - 22:36
Takeda Pharmaceutical to invest $30bn in US over 5 years: CEO (Nikkei)
 
Um den gesamten Artikel unter asia.nikkei.com zu lesen, klicken Sie bitte auf die Überschrift...
08.05.25 - 08:54
Takeda Pharmaceutical Non-GAAP EPS of ¥491.00, revenue of ¥4581.6B; initiates FY25 outlook (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.05.25 - 08:39
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress (Business Wire)
 
Core Revenue Growth of 7.4% at Actual Exchange Rates (AER), + 2.8% at Constant Exchange Rate (CER) in FY2024 Core Operating Profit Growth of 4.9% at CER with Efficiency Program Driving Cost Savings Up to Six New Molecular Entities in Phase 3 Development in FY2025 with Three Phase 3 Data Readouts Recently Completed or Anticipated FY2025 Outlook for Broadly Flat Revenue and Core Profit Reflecting Product Momentum and Increasing Investment in New Launch Preparation Proposed Dividend Increase from JPY 196 to JPY 200 OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management. Takeda has built a high-value late-stage pipeline with potentially life-transforming new treatment options for patients. Following a positive Phase 3 readout for rusfertide...
07.05.25 - 19:45
Takeda Pharmaceutical Co. (TAK) Upgraded to Strong Buy: Here′s What You Should Know (Zacks)
 
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....
07.05.25 - 18:12
Takeda Pharmaceutical FY Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
06.05.25 - 15:12
Klimaeffizienz und regionale Verantwortung: Takeda eröffnet Biomasseheizwerk in Singen (News Aktuell)
 
Takeda Pharma Vertrieb GmbH & Co. KG: Singen (ots) - - 14,5 Millionen Euro Investition am Standort Singen - nachhaltige Transformation vorangetrieben - Biomasseheizwerk leistet Beitrag zur regionalen Kreislaufwirtschaft und wird Reduktion von bis zu 80 Prozent CO2-Emissionen am Standort ......
05.05.25 - 15:27
Novavax reports revised terms for Takeda agreement for Nuvaxovid in Japan (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.05.25 - 14:48
Novavax Announces Improved Financial Terms In Its Agreement With Takeda For Nuvaxovid In Japan (AFX)
 
TOKYO (dpa-AFX) - Novavax, Inc. (NVAX) said it has updated the terms of the collaboration and licensing agreement with Takeda. The company noted that the improved financial terms of the amended ag......
30.04.25 - 19:45
Are You Looking for a Top Momentum Pick? Why Takeda Pharmaceutical Co. (TAK) is a Great Choice (Zacks)
 
Does Takeda Pharmaceutical Co. (TAK) have what it takes to be a top stock pick for momentum investors? Let's find out....
23.04.25 - 00:12
How Takedas CEO transformed the company into a global pharma powerhouse (CNBC)
 
Takeda Pharmaceuticals, Japan's largest drugmaker, has undergone a sweeping transformation under CEO Christophe Weber, emerging as one of the world's leading pharmaceutical companies....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Was man zu lang bedenkt, das wird bedenklich. - Sprichwort
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!